Delivery of RNA therapeutics using circular nucleic acids

Ring-shaped oligonucleotides form a cyclic structure to address nuclease stability and inflammatory issues, enhancing RNA therapeutic efficacy by reducing PRR interactions and enabling controlled activation for targeted RNA regulation.

JP2026521760APending Publication Date: 2026-07-01ARNAY SCI LLC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
ARNAY SCI LLC
Filing Date
2024-06-21
Publication Date
2026-07-01

AI Technical Summary

Technical Problem

Existing antisense oligonucleotides face challenges with nuclease stability and inflammatory responses, leading to reduced therapeutic efficacy and safety concerns due to interactions with pattern recognition receptors.

Method used

Development of ring-shaped oligonucleotides (RSOs) that form an intermolecular cyclic structure through complementary oligonucleotides, masking the 5' and 3' ends to reduce interaction with PRRs and enhance nuclease stability, while allowing conditional release of the functional oligonucleotide for targeted RNA regulation.

Benefits of technology

RSOs improve nuclease stability, reduce inflammatory responses, and enhance delivery and functionality of RNA therapeutics by minimizing off-target interactions and enabling controlled activation within cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026521760000001_ABST
    Figure 2026521760000001_ABST
Patent Text Reader

Abstract

The present invention provides oligonucleotides referred to as cyclic oligonucleotides ("RSOs") as described herein, compositions comprising the same, and methods of using the same. In certain embodiments, it comprises two oligonucleotides, the first oligonucleotide comprising a functional oligonucleotide and the second oligonucleotide comprising a complementary oligonucleotide, the first oligonucleotide and the second oligonucleotide hybridizing to form two double-stranded portions, the 5' end of the first oligonucleotide being adjacent to the 3' end of the first oligonucleotide, thereby forming a ring.
Need to check novelty before this filing date? Find Prior Art